Home>>Signaling Pathways>> Tyrosine Kinase>> PDGFR>>Ki20227

Ki20227 Sale

(Synonyms: Ki 20227;Ki-20227) 目录号 : GC13264

A c-Fms kinase inhibitor

Ki20227 Chemical Structure

Cas No.:623142-96-1

规格 价格 库存 购买数量
10mg
¥1,439.00
现货
50mg
¥5,828.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

The IC50s of Ki20227 inhibiting c-Fms, stem cell factor receptor (c-Kit), vascular endothelial growth factor receptor-2 (KDR), and platelet-derived growth factor receptor B were found to be 2, 451, 12, and 217 nmol/L, respectively.

Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response. Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)-oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl] urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor.

In vitro: Ki20227 was found to inhibit c-Fms, KDR, c-Kit, and platelet-derived growth factor receptor B, but not inhibit other kinases tested, such as epidermal growth factor receptor, fms-like tyrosine kinase-3 , or c-Src. Ki20227 was also found to inhibit the M-CSF dependent growth of M-NFS-60 cells but not the M-CSF independent growth of A375 human melanoma cells. Furthermore, Ki20227 inhibited the development of tartrate-resistant acid phosphatase-positive osteoclast-like cells in a dose-dependent manner [1].

In vivo: Oral administration of Ki20227 suppressed osteoclast-like cell accumulation and bone resorption induced by metastatic tumor cells in nude rats following intracardiac injection of A375 cells. In addition, Ki20227 decreased the number of tartrate-resistant acid phosphatase-positive osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats [1].

Clinical trial: Ki20227 is currently in the preclinical developlent stage and no clinical data are available.

Reference:
[1] Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.   A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006;5(11):2634-43.

Chemical Properties

Cas No. 623142-96-1 SDF
别名 Ki 20227;Ki-20227
化学名 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea
Canonical SMILES CC(C1=NC=CS1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OC
分子式 C24H24N4O5S 分子量 480.55
溶解度 ≥ 48.1 mg/mL in DMSO, ≥ 8.6 mg/mL in EtOH with ultrasonic and warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0809 mL 10.4047 mL 20.8095 mL
5 mM 0.4162 mL 2.0809 mL 4.1619 mL
10 mM 0.2081 mL 1.0405 mL 2.0809 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置